311 related articles for article (PubMed ID: 25983109)
1. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.
García-Layana A; Figueroa MS; Araiz J; Ruiz-Moreno JM; Gómez-Ulla F; Arias-Barquet L; Reiter N
Drugs Aging; 2015 Oct; 32(10):797-807. PubMed ID: 26442858
[TBL] [Abstract][Full Text] [Related]
3. Treatment of age-related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4-year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial).
Airody A; Baseler HA; Seymour J; Allgar V; Mukherjee R; Downey L; Dhar-Munshi S; Mahmood S; Balaskas K; Empeslidis T; Hanson RLW; Dorey T; Szczerbicki T; Sivaprasad S; Gale RP
Acta Ophthalmol; 2024 May; 102(3):e328-e338. PubMed ID: 37776074
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05.
Koch R; Schmidt M; Gebauer S; Busse H; Uhlig CE
BMC Ophthalmol; 2015 Oct; 15():138. PubMed ID: 26490832
[TBL] [Abstract][Full Text] [Related]
5. Switching to the aflibercept (3 mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes.
Feng C; Chu W; Lin P; Xu H; Chen X
Medicine (Baltimore); 2024 Apr; 103(16):e37839. PubMed ID: 38640269
[TBL] [Abstract][Full Text] [Related]
6. Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
Lee JH; Kim JH
J Ocul Pharmacol Ther; 2024 Mar; 40(2):136-143. PubMed ID: 38489060
[No Abstract] [Full Text] [Related]
7. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
[TBL] [Abstract][Full Text] [Related]
8. LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Muftuoglu IK; Alam M; You QS; Gaber R; Ramkumar HL; Mendoza N; Meshi A; Freeman WR
Retina; 2018 Mar; 38(3):516-522. PubMed ID: 28221254
[TBL] [Abstract][Full Text] [Related]
9. Ganglion cell complex changes in wet AMD patients treated with anti-VEGF intravitreal injections according to a treat-and-extend protocol.
Cao J; Mongy M; Ferreira L; Brent MH
Can J Ophthalmol; 2024 Apr; 59(2):96-101. PubMed ID: 36535380
[TBL] [Abstract][Full Text] [Related]
10. Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.
Zhang X; Lai TYY
Biomed Res Int; 2018; 2018():9640131. PubMed ID: 29682574
[TBL] [Abstract][Full Text] [Related]
11. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis.
Cui C; Lu H
Clin Interv Aging; 2018; 13():51-62. PubMed ID: 29343949
[TBL] [Abstract][Full Text] [Related]
12. SUCCESSFUL TREATMENT OF SEVERE PERIPAPILLARY PACHYCHOROID SYNDROME WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Abraham N; Bousquet E; Santina A; Somisetty S; Romero-Morales V; Sarraf D
Retin Cases Brief Rep; 2024 May; 18(3):279-284. PubMed ID: 36800535
[TBL] [Abstract][Full Text] [Related]
13. Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.
Pereira DS; Maturi RK; Akita K; Mahesh V; Bhisitkul RB; Nishihata T; Sakota E; Ali Y; Nakamura E; Bezwada P; Nakamura Y
Eye (Lond); 2024 Apr; 38(6):1140-1148. PubMed ID: 38036609
[TBL] [Abstract][Full Text] [Related]
14. Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Ying GS; Maguire MG; Daniel E; Grunwald JE; Ahmed O; Martin DF;
Ophthalmology; 2016 Feb; 123(2):352-360. PubMed ID: 26545320
[TBL] [Abstract][Full Text] [Related]
15. Comparative Study on Anti-VEGF in Wet Age-Related Macular Degeneration in the Setting Based on Lean Methodology from the Bari Intravitreal Injection Registry (BIVIR).
Grassi MO; Viggiano P; Borrelli E; Boscia G; Molfetta T; Malerba MG; D'Addario M; Giancipoli E; Alessio G; Boscia F
Ophthalmol Ther; 2024 Jun; 13(6):1619-1634. PubMed ID: 38619788
[TBL] [Abstract][Full Text] [Related]
16. Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy.
Videkar C; Kapoor A; Chhablani J; Narayanan R
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26682842
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degeneration.
Ota H; Kataoka K; Asai K; Takeuchi J; Nakano Y; Nakamura K; Todoroki T; Nishiguchi KM
Graefes Arch Clin Exp Ophthalmol; 2024 May; ():. PubMed ID: 38758378
[TBL] [Abstract][Full Text] [Related]
18. The Reinforced Treat-and-Extend Protocol for Exudative Age-Related Macular Degeneration: Retrospective Assessment of 24-Month Real-World Outcomes in France.
Roubelat FP; Barioulet L; Varenne F; Escudier C; Meyer P; Gomane C; Butterworth J; Pagot-Mathis V; Fournié P; Gualino V; Soler V
Ophthalmol Ther; 2024 Jun; 13(6):1647-1667. PubMed ID: 38625500
[TBL] [Abstract][Full Text] [Related]
19. A quantitative sonoelastography evaluation of ocular and periocular elasticity after intravitreal ranibizumab injection.
Sayin N; Kocak I; Pehlivanoğlu S; Pekel G; Er A; Bayramoğlu SE; Aydin A
J Fr Ophtalmol; 2023 Nov; 46(9):1030-1038. PubMed ID: 37598105
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Regulation of Endothelial Cells: A New Era for Treating Wet Age-Related Macular Degeneration.
Chen X; Xu Y; Ju Y; Gu P
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
